{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:11:53Z","timestamp":1793376713007,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-023-00801-1","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T07:04:08Z","timestamp":1676876648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1075-0959","authenticated-orcid":false,"given":"Kathryn T.","family":"Maples","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9412-4025","authenticated-orcid":false,"given":"Kevin H.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha S.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4816-1607","authenticated-orcid":false,"given":"Craig C.","family":"Hofmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-2338","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8249-5988","authenticated-orcid":false,"given":"Madhav V.","family":"Dhodapkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5687-6429","authenticated-orcid":false,"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-6869","authenticated-orcid":false,"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-9323","authenticated-orcid":false,"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"801_CR1","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1177\/10600280211058754","volume":"56","author":"JR Arnall","year":"2022","unstructured":"Arnall JR, Maples KT, Harvey RD, Moore DC. Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations. Ann Pharmacother. 2022;56:927\u201340.","journal-title":"Ann Pharmacother"},{"key":"801_CR2","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1182\/bloodadvances.2018020883","volume":"2","author":"C Schuetz","year":"2018","unstructured":"Schuetz C, Hoenig M, Moshous D, Weinstock C, Castelle M, Bendavid M, et al. Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv. 2018;2:2550\u201353.","journal-title":"Blood Adv"},{"key":"801_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-020-01020-y","volume":"14","author":"H Huang","year":"2021","unstructured":"Huang H, Zhu J, Yao M, Kim TM, Yoon DH, Cho SG, et al. Daratumumab monotherapy for patients with relapsed or refractory natural killer\/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. J Hematol Oncol. 2021;14:25.","journal-title":"J Hematol Oncol"},{"key":"801_CR4","unstructured":"Darzalex (daratumumab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; March 2022."},{"key":"801_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1139\/cjpp-2014-0410","volume":"93","author":"AG Guedes","year":"2015","unstructured":"Guedes AG, Deshpande DA, Dileepan M, Walseth TF, Panettieri RA, Subramanian S, et al. CD38 and airway hyper-responsiveness: studies on human airway smooth muscle cells and mouse models. Can J Physiol Pharm. 2015;93:145\u201353.","journal-title":"Can J Physiol Pharm"},{"key":"801_CR6","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","volume":"387","author":"S Lonial","year":"2016","unstructured":"Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016;387:1551\u201360.","journal-title":"Lancet"},{"key":"801_CR7","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1038\/s41375-018-0120-2","volume":"32","author":"H Barr","year":"2018","unstructured":"Barr H, Dempsey J, Waller A, Huang Y, Williams N, Sharma N, et al. Ninety-minute daratumumab infusion is safe in multiple myeloma. Leukemia 2018;32:2495\u2013518.","journal-title":"Leukemia"},{"key":"801_CR8","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","volume":"7","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7:e370\u201380.","journal-title":"Lancet Haematol"},{"key":"801_CR9","unstructured":"Darzalex Faspro (daratumumab\/hyaluronidase) [prescribing information]. Horsham, PA: Janssen Biotech Inc; November 2022."},{"key":"801_CR10","doi-asserted-by":"publisher","first-page":"e680","DOI":"10.1016\/j.clml.2022.03.006","volume":"22","author":"JA Davis","year":"2022","unstructured":"Davis JA, Youngberg H, Gaffney K, Duco M, Hashmi H. \u2018Fast but not so Furious\u2019: Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy. Clin Lymphoma Myeloma Leuk. 2022;22:e680\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00801-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00801-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00801-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T07:05:33Z","timestamp":1676876733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00801-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["801"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00801-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"20 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MD serves as Consultant for Amgen, Celgene, Janssen, Kite Pharma, lava therapeutics, and Roche\/Genentech. CH receives research funding from Bristol-Myers Squibb, Celgene, and Cellularity and is a Consultant for Celgene, Imbrium, Janssen, Karyopharm, Nektar, Oncopeptides, and Sanofi Pasteur. JK receives research funding from Abbvie\/Genentech, Amgen, Bristol-Myers Squibb, Gelgene, Fortis Therapeutics, Janssen, Merck, and Sutro Biopharm, Inc and is a Consultant for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Karyopharm Therapetuics, Sanofi, Takeda, Ecnofarma, and TG Therapeutics. SL receives research funding from Bristol-Myers Squibb, Celgene, and Takeda. He is a Consultant for Abbvie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Juno Therapeutics, Merck, Novartis, and Takeda. KM has served as Consultant for Janssen. AN receives research funding from Amgen, Janssen, and Takeda. He is a Consultant for Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Sanofi Pharmaceuticals, and Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}